Following a slight dip in the last session, Eli Lilly (LLY) shares gained ~5% on Monday as Leerink Partners upgraded the ...
Eli Lilly shares were upgraded to Outperform at Leerink Partners, which cited “multiple waves of obesity treatment adoption drivers” and raised its price target to $1,104 from $886.
Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to ...
In late-stage studies, Merck & Co.’s PCSK9-targeted pill achieved low-density lipoprotein cholesterol (LDL-C) reductions ...
The number of biopharma M&A deals announced so far this year is higher than the yearly average for the last 15 years, while deal value has already eclipsed last year’s total. | The number of biopharma ...
Fintel reports that on November 10, 2025, Leerink Partners maintained coverage of uniQure N.V. (NasdaqGS:QURE) with a ...
Cogent Biosciences expects to file a new drug application for bezuclastinib in gastrointestinal stromal tumors early next ...
Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co., Truist Securities and LifeSci Capital are acting as ...
The gross proceeds to Evommune from the initial public offering before deducting underwriting discounts and commissions and offering expenses were $172.5 million. The shares began trading on the New ...
Exelixis, Inc. (NASDAQ:EXEL) is one of the most profitable biotech stocks to buy. On October 21, Exelixis, Inc. (NASDAQ:EXEL) got upgraded to Outperform from Market Perform by Leerink Partners. The ...
As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...
MoonLake intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, to fund the research and development of sonelokimab and for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback